Chronic effects of different dosage of diltiazem on patients with coronary slow flow phenomenon

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002513

Enrollment

Unknown

Registered

2012-09-12

Start date

2012-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Slow Flow

Interventions

Two groups:standard dose versus large dose of diltiazem release capsules

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Eighty patient with chest pain anddiagnosed as CSF using the corrected (corrected TIMI frame count, CTFC) method from 2012 to the end of this test in our department were included

Exclusion criteria

Exclusion criteria: 1. A history of myocardial infarction or coronary angioplasty; 2. Cardiomyopathy, valvular disease, hypertensive heart disease, congenital heart disease; 3. Coronary artery dilatation, stenosis (stenosis> 40%); 4. Systolic blood pressure =III; 7. Liver or renal dysfunction (serum aspartate transaminase or alanine transaminase ALT increased by 2-fold, creatinine >=2mg/dL); 8. Study drug allergy.

Design outcomes

Primary

Measure	Time frame
Symptom;	—

Countries

China

Contacts

Public ContactGu Ye

yegu2003@163.com+86 13971010080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026